Therapeutic knockdown of MLKL reduces diet-induced obesity and promotes insulin sensitivity. (#6)
Taaseen Rahman
1
,
Masaaki Sato
1
,
Kritima Dhakal
2
,
Xichun Li
2
,
Yizhuo Wang
2
,
Benjamin Weger
2
,
Matt Sweet
2
,
Frederic Gachon
2
,
James Murphy
3
,
Richard Lee
4
,
Adam Mullick
4
,
Denuja Karunakaran
1
2
- Monash Biomedicine Discovery Institute and Victorian Heart Institute, Clatyton, VIC, Australia
- Institute for Molecular Bioscience, The University of Queensland , Brisbane , QLD , Australia
- Inflammation Division, Walter and Eliza Hall Institute of Medical Research , Melbourne , VIC , Australia
- Cardiovascular Drug Discovery, CIonis Pharmaceuticals, Inc, San Diego, California, USA
Publish consent withheld
- Karunakaran, D., Turner, A., Duchez, A-C., Soubeyrand, S., Rasheed, A., Smyth, D., Cook, D. P., Nikpay, M., Kandiah, JW., Pan, C., Geoffrion, M., Lee, R., Boytard, L,, Wyatt, H., Nguyen, M-A., Lau, P., Laakso, M., Ramkhelawon, B., Alvarez, M., Pietilainen, K. H., Pajukanta, P., Vanderhyden, B.C., Liu, P., Berger, S.B., Gough, P.J., Bertin, J., Harper, M-E., Lusis, A.J., McPherson, R., Rayner, KJ (2020) RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice, Nature Metabolism, 2: 1113–1125.